The new Ukrainian airline Bees Airline in April-June launches regular direct flights from Kyiv to Tbilisi, Batumi and Yerevan, as well as from Odesa to Yerevan.
According to the press service of Kyiv Sikorsky International Airport, in particular, Kyiv-Tbilisi-Kyiv flights will be launched from April 30 and will be operated on Tuesdays and Fridays, and from June 6 additionally on Sundays.
Kyiv-Batumi-Kyiv flights will be operated from June 9 on Mondays, Wednesdays, Fridays and Sundays.
Kyiv-Yerevan-Kyiv flights will be launched from April 29 on Mondays and Thursdays.
Odesa-Yerevan-Odesa flights will start from June 14 on Mondays and Fridays.
In addition to Bees Airline, UIA and SkyUp also operate direct flights from Kyiv to Tbilisi, and SkyUp to Batumi. UIA also operates direct flights from Kyiv to Yerevan.
As reported, the State Aviation Administration of Ukraine issued an operator certificate to Bees Airline on March 12, 2021. Later, the regulator allowed the company to operate flights on 31 routes – 15 regular and 16 charter.
The volume of investments planned by VR Capital in the launch of three wind power plants in Odesa region with a total design capacity of 49.5 MW will amount to EUR 75 million, the company said on Thursday.
According to the report, after setting the permission of the Antimonopoly Committee, on March 31 in Odesa, three transactions of purchase and sale of corporate rights were carried out with Artsyz Wind Farm LLC, Artsyz Wind Farm 2 LLC and Kyiska Wind Farm LLC, as a result of which the company received all 100% of these rights.
According to the report, the seller of 68.61% was a corporate investment fund (CIF) owned by the owner of Metropoliya Group of Companies Viktor Kurtev, the sellers of 31.39% were Yuriy Kostrobiy and Oksana Kozachok, who in 2020 carry out intermediate financing of projects at the development stage.
After the sale of three wind farms, the Metropoliya Group, which has carried out the development part of projects, in particular, land acquisition projects, passing the environmental impact assessment procedure, concluding preliminary agreements with the state-owned enterprise Guaranteed Buyer, will continue technical support of the projects until they are put into commercial operation in 2022, VR Capital said.
ICU, the leading Ukrainian asset manager and government bond broker, today announced the launch of ICU Global Equity Index, a closed qualified mutual investment fund with an issue size of UAH 130 million. “Through the ICU Global Equity Index Fund, local private and institutional investors can invest in Exchange-Traded Funds (ETFs) of various sectors of the economy, in particular, NASDAQ and S&P 500, as well as other indices including gold, health, consumer and Asian companies,” ICU said in a report on Thursday.
In early March the National Securities and Stock Market Commission of Ukraine confirmed the fund complied with the asset size requirements.
“We have been seeing a lot of demand from investors to invest in foreign instruments, so we decided to expand our offering by adding an index fund in foreign currency to meet client demand,” Head of Asset Management at ICU Group Hryhoriy Ovcharenko said.
He said that the fund’s retrospective results for the last 15 years (including crisis periods) more than doubled the benchmark – the yield of the S&P 500, proofing the strategy’s effectiveness.
ICU is an independent asset management and investment advisory firm specializing in the emerging markets of Central and Eastern Europe. Founded in 2006 by senior investment professionals from ING, ICU is Ukraine’s leading asset manager with over $500 million in assets under management.
Makar Paseniuk and Kostiantyn Stetsenko are founding partners of ICU.
Vienna Insurance Group, together with three other investors, created the investment company Venpace GmbH & Co. KG formed in Cologne, which aims to find, financially support and make use of young international technology companies, according to a group’s press release.
According to it, in addition to Vienna Insurance Group, which holds a 25% stake in the new company, Ideal Insurance Group, Provinzial Rheinland Versicherung AG and Prisma Life AG also became the investors and founders of Venpace.
“We want to take advantage of the growing insurtech scene and its innovative ideas to further expand our range of digital products and services. We are intentionally investing in the early stage of future-oriented start-ups, in order to generate medium-term returns while spreading the risk over multiple investors,” CEO Elisabeth Stadler said.
Venpace might also be used for corporate venturing aimed at realising ideas with start-ups founded specifically for this purpose. The initial focus will be on life insurance and digital points of contact with customers.
The new investment company will build up and manage equity investments in technology companies over a period of ten years. The minimum investment of the four shareholders is EUR 1 million over the next five years. In addition, investors can invest directly in companies of interest to them through Venpace and thus efficiently leverage the start-up expertise and capacities of the investment company.
The list of specialized organizations that will procure medicines and medical products in 2021 was approved by the government at the Wednesday meeting.
According to the document, the Crown Agents British purchasing agency will procure: tests, consumables for the diagnosis of tuberculosis; immunobiological medicines for immunoprophylaxis of the population and products to ensure control of immunobiological preparations and medical devices; medicines for children with dwarfism of various origins; medical products for citizens suffering from epidermolysis bullosa; medicines for patients in the pre- and postoperative period of transplantation; consumables for determining the level of glucose in the blood, glycated hemoglobin; medicines for children with mental and behavioral disorders from the autism spectrum, with schizophrenia, affective disorders, hyperkinetic disorders and epilepsy; endoprostheses and implantation kits.
The United Nations Development Program (UNDP) will procure: medicines for citizens with viral hepatitis B and C; test systems for diagnosing HIV infection, accompanying antiretroviral therapy and monitoring the course of HIV infection in patients, determining the resistance of the virus, conducting reference studies; medicines and medical products to ensure the development of donation of blood and its components.
